BorgWarner Inc.
BWABorgWarner Inc.'s price has outrun its earnings. +68.0% in a year against EPS −14.7% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +68.0% in a year while annual EPS moved −14.7% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (46 weeks in) while the P/E sits at the 80th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +52.9% year on year, and 310% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
BorgWarner Inc. trades at $63.0, in a confirmed uptrend and 46 weeks into that stage. That is +14.6% against its own 200-day average. It sits at 66% of a 52-week range of $41 to $75. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a confirmed uptrend — week 46 of stage 2. At $63.0 it trades +14.6% versus its 200-day average and sits at 66% of its 52-week range ($41–$75).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +106% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-31) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
BorgWarner Inc. trades at 37.3× P/E, at the pricey end of its own range (80th percentile). Its long-run median P/E is 13.5×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 37.3× is at the pricey end of its own range (80th percentile), against a long-run median of 13.5× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −14.7% against a +68.0% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +14.0%/yr price move, ~−21.6%/yr came from earnings growth and ~+35.6 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
BorgWarner Inc. reads as turning around on its fundamental arc. Turning around — profit growth swung from −66.7% at the trough to +20.0%, a 2-quarter improving streak, ROCE holding at 6.1%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +1.6% | +4.3% | — | — |
| Profit | −15.0% | −30.9% | — | — |
| EPS | −14.7% | −21.9% | — | — |
| Stock price | +68.0% | +14.0% | +6.7% | +6.6% |
4-Factor Sector Score
57.2/100 — rank 4 of 29 in Auto Parts · 66% evidence confidence
BorgWarner Inc. scores 57.2 out of 100 against the 29 companies it is compared with in Auto Parts, ranking 4. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 20.7 + 12.1 + 10.9 + 13.5 = 57.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
BorgWarner Inc. reported $3.5 B of revenue in the Mar 26 quarter, +0.3% year on year. That is the 4th straight quarter of year-on-year growth. Over 4 years it has compounded at 5.0% a year. The last full year, FY25, came in at $14.3 B. The last four reported quarters add to $14.3 B.
FY25 revenue came in at $14.3 B (+1.6% on the year), capping 4 years at 5.0% compound. The latest quarter (Mar 26) printed $3.5 B, +0.3% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +2.3% growth against the decade's 5.0% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +2.3% over the last 4 quarters against −0.3%/yr over the last 8 — stabilising; TTM profit +20.0% vs −21.4%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
BorgWarner Inc.'s operating margin is 9.6% in the Mar 26 quarter, +2.8 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 3.8% to 8.2%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 9.6%, +2.8 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 3.8%–8.2%.
Why the margin moved: operating margin went +2.8 pp year on year while gross margin went +1.1 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
BorgWarner Inc. earned $0.3 B of net profit in the Mar 26 quarter, +52.9% year on year. Full-year FY25 profit was $0.3 B. The 4-year compound rate is −14.6%. That is 7.4% of the quarter's revenue. The same quarter a year earlier earned $0.2 B. 2 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.3 B, +52.9% year on year. On the full year, FY25 printed $0.3 B (−15.0%), and the 4-year compound rate is −14.6%.
Why profit moved: revenue contributed +0.3% and the margin +2.8 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit −2.4% vs revenue +2.3%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 310% of BorgWarner Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $1.6 B of operating cash against $0.3 B of profit. After $0.5 B of capital spending, $1.2 B was left as free cash.
FY25: operating cash of $1.6 B against reported profit of $0.3 B, leaving free cash of $1.2 B after $0.5 B of capital spending. Across the last 3 fiscal years the conversion rate is 310% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
BorgWarner Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $2.0 B over the last 3 years. Averaged over those years that is 4.7% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $2.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
BorgWarner Inc. earns a ROE of 6% in FY25. Return on invested capital clears the cost of that capital by +4.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 2.4% net margin on 1.04× asset turns.
FY25 ROE is 6%.
Why the return is what it is — the wiring (FY25): 2.4% net margin × 1.04× asset turns × 2.45× balance-sheet leverage ≈ 6.1% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 12.4% − 8.1% = a +4.3 pp spread. The 8.1% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
BorgWarner Inc. paid $0.62 per share over the last four reported quarters, up 54.5% on a year ago. The most recent declaration was $0.17 for Mar 26. Against the current price of $63.0 that is a trailing yield of 0.98%, measured on dividends already paid rather than on a forecast.
BorgWarner Inc. paid $0.62 per share across the last four reported quarters, most recently $0.17 for Mar 26. That is up 54.5% against the same quarter a year earlier. Against the current price of $63.0 the trailing twelve months work out to 0.98% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
BorgWarner Inc. carries total debt of $3.9 B against shareholder equity of $5.6 B as of Mar 26, a debt-to-equity of 0.69. On the annual view that ratio went from 0.60 in FY21 to 0.70 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $3.9 B against shareholder equity of $5.6 B — a debt-to-equity of 0.69. On the annual view, debt-to-equity went from 0.60 (FY21) to 0.70 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
4.5% of BorgWarner Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 3.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 4.5% of the float is sold short, and at typical trading volumes it would take about 3.5 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
BorgWarner Inc.: the Z-score reads 3.06. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.06 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.06.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Garrett Motion Inc.GTX | 64.4/100Thin evidence · provisional56% evidence | FADING | 21.7/35 Revenue — · PAT — · OPM change 1 pp 39% evidence | 18.3/25 ROCE 14.2% · OPM 13.9% 76% evidence | 10.1/20 P/E 19.9× · PEG — 15% evidence | 14.3/20 RS sector 39.8% · RS bench 35.8% · 1Y 148.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 18.3 + 10.1 + 14.3 = 64.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Douglas Dynamics, Inc.PLOW | 58.4/100Thin evidence · provisional55% evidence | ASLEEP | 21.8/35 Revenue 15.5% · PAT -17.2% · OPM change 4.4 pp 40% evidence | 9.3/25 ROCE 1.9% · OPM 7.2% 57% evidence | 13.0/20 P/E 19× · PEG 1.04 65% evidence | 14.3/20 RS sector 6.2% · RS bench 3% · 1Y 44.4%3 of 12 weeks ahead 70% evidence |
| Exact sum: 21.8 + 9.3 + 13 + 14.3 = 58.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Allison Transmission Holdings, Inc.ALSN | 57.4/100Mixed-positive evidence66% evidence | ASLEEP | 13.8/35 Revenue 14% · PAT -28% · OPM change -18.6 pp 53% evidence | 13.7/25 ROCE 3.2% · OPM 13.9% 57% evidence | 14.8/20 P/E 18.2× · PEG 0.71 65% evidence | 15.1/20 RS sector 7.7% · RS bench 4.4% · 1Y 39.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 13.7 + 14.8 + 15.1 = 57.4 · Decision use: Price leads the evidence: RS versus the benchmark is 4.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 4BorgWarner Inc.this pageBWA | 57.2/100Mixed-positive evidence66% evidence | FADING | 20.7/35 Revenue 2.3% · PAT 20.1% · OPM change 2.8 pp 53% evidence | 12.1/25 ROCE 3.2% · OPM 9.5% 57% evidence | 10.9/20 P/E 32.1× · PEG 1.19 65% evidence | 13.5/20 RS sector 10.8% · RS bench 7.4% · 1Y 63.6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 12.1 + 10.9 + 13.5 = 57.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Magna International Inc.MGA | 56.8/100Thin evidence · provisional56% evidence | TURNING | 19.5/35 Revenue — · PAT — · OPM change 1.2 pp 39% evidence | 10.2/25 ROCE 3.1% · OPM 4.3% 76% evidence | 9.5/20 P/E 24.1× · PEG — 15% evidence | 17.6/20 RS sector 16.4% · RS bench 12.9% · 1Y 64.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 10.2 + 9.5 + 17.6 = 56.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Atmus Filtration Technologies Inc.ATMU | 53.0/100Mixed-positive evidence66% evidence | ASLEEP | 19.2/35 Revenue 10% · PAT 14.1% · OPM change 1 pp 53% evidence | 14.9/25 ROCE 5.8% · OPM 14.4% 57% evidence | 10.4/20 P/E 22.3× · PEG 1.45 65% evidence | 8.5/20 RS sector -2.5% · RS bench -5.5% · 1Y 34.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 14.9 + 10.4 + 8.5 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7O'Reilly Automotive, Inc.ORLY | 53.0/100Thin evidence · provisional56% evidence | BASING | 18.5/35 Revenue — · PAT — · OPM change 0.6 pp 39% evidence | 18.5/25 ROCE 13.2% · OPM 18.5% 76% evidence | 9.2/20 P/E 29.3× · PEG — 15% evidence | 6.8/20 RS sector -10.9% · RS bench -13.5% · 1Y -11.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 18.5 + 9.2 + 6.8 = 53 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Gentex CorporationGNTX | 52.9/100Thin evidence · provisional56% evidence | ASLEEP | 18.3/35 Revenue — · PAT — · OPM change -1.3 pp 39% evidence | 15.9/25 ROCE 5.6% · OPM 18.3% 76% evidence | 10.9/20 P/E 13.4× · PEG — 15% evidence | 7.8/20 RS sector -8.2% · RS bench -11% · 1Y -9.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.3 + 15.9 + 10.9 + 7.8 = 52.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Advance Auto Parts, Inc.AAP | 51.4/100Thin evidence · provisional56% evidence | TURNING | 22.5/35 Revenue — · PAT — · OPM change 7.7 pp 39% evidence | 6.4/25 ROCE 1% · OPM 2.6% 76% evidence | 8.7/20 P/E 80.8× · PEG — 15% evidence | 13.8/20 RS sector 1.4% · RS bench -1.7% · 1Y -0.4%4 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 6.4 + 8.7 + 13.8 = 51.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10PHINIA Inc.PHIN | 51.2/100Thin evidence · provisional56% evidence | ASLEEP | 17.9/35 Revenue — · PAT — · OPM change 0.1 pp 39% evidence | 10.3/25 ROCE 2.8% · OPM 7.9% 76% evidence | 9.7/20 P/E 23.6× · PEG — 15% evidence | 13.3/20 RS sector 10.8% · RS bench 7.4% · 1Y 53.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 10.3 + 9.7 + 13.3 = 51.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11XPEL, Inc.XPEL | 50.7/100Thin evidence · provisional60% evidence | TURNING | 19.8/35 Revenue 12.4% · PAT 12.5% · OPM change 0.4 pp 53% evidence | 14.0/25 ROCE 4.6% · OPM 11.1% 57% evidence | 8.1/20 P/E 23.2× · PEG 1.98 65% evidence | 8.8/20 RS sector -2.6% · RS bench -5.6% · 1Y 36.7%2 of 12 weeks ahead 70% evidence |
| Exact sum: 19.8 + 14 + 8.1 + 8.8 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Genuine Parts CompanyGPC | 49.3/100Thin evidence · provisional56% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change -0.3 pp 39% evidence | 10.4/25 ROCE 3% · OPM 4.6% 76% evidence | 8.5/20 P/E 471.9× · PEG — 15% evidence | 13.1/20 RS sector -0.7% · RS bench -3.7% · 1Y -0.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 10.4 + 8.5 + 13.1 = 49.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Dorman Products, Inc.DORM | 49.1/100Mixed-negative evidence66% evidence | BREAKING OUT | 13.3/35 Revenue 5% · PAT -11.2% · OPM change -4.7 pp 53% evidence | 12.5/25 ROCE 3% · OPM 11.1% 57% evidence | 7.5/20 P/E 16.9× · PEG 2.33 65% evidence | 15.8/20 RS sector 4.1% · RS bench 1% · 1Y 5.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 12.5 + 7.5 + 15.8 = 49.1 · Decision use: Price leads the evidence: RS versus the benchmark is 1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 14Autoliv, Inc.ALV | 48.5/100Thin evidence · provisional56% evidence | ASLEEP | 14.9/35 Revenue — · PAT — · OPM change -1.3 pp 39% evidence | 13.7/25 ROCE 4.3% · OPM 8.6% 76% evidence | 10.8/20 P/E 13.6× · PEG — 15% evidence | 9.1/20 RS sector -3.7% · RS bench -6.5% · 1Y 10.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 14.9 + 13.7 + 10.8 + 9.1 = 48.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Gentherm IncorporatedTHRM | 47.5/100Thin evidence · provisional56% evidence | BREAKING OUT | 13.3/35 Revenue — · PAT — · OPM change -1.9 pp 39% evidence | 6.2/25 ROCE 1% · OPM 2.9% 76% evidence | 9.0/20 P/E 39.2× · PEG — 15% evidence | 19.0/20 RS sector 15.3% · RS bench 12% · 1Y 31.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 6.2 + 9 + 19 = 47.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Lear CorporationLEA | 45.6/100Thin evidence · provisional56% evidence | ASLEEP | 19.1/35 Revenue — · PAT — · OPM change 0.3 pp 39% evidence | 9.7/25 ROCE 2.9% · OPM 4.4% 76% evidence | 11.3/20 P/E 12.2× · PEG — 15% evidence | 5.5/20 RS sector -3.5% · RS bench -6.4% · 1Y 31.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 9.7 + 11.3 + 5.5 = 45.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Modine Manufacturing CompanyMOD | 42.3/100Thin evidence · provisional56% evidence | ASLEEP | 15.7/35 Revenue — · PAT — · OPM change -0.6 pp 39% evidence | 12.6/25 ROCE 4% · OPM 10.9% 76% evidence | 8.6/20 P/E 100.4× · PEG — 15% evidence | 5.4/20 RS sector -2.9% · RS bench -5.9% · 1Y 48.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 12.6 + 8.6 + 5.4 = 42.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18AutoZone, Inc.AZO | 41.8/100Mixed-negative evidence81% evidence | BASING | 15.6/35 Revenue 5.8% · PAT -3.3% · OPM change -0.3 pp 83% evidence | 17.0/25 ROCE 9.2% · OPM 19.1% 76% evidence | 5.8/20 P/E 24× · PEG 2.4 65% evidence | 3.4/20 RS sector -22.3% · RS bench -24.6% · 1Y -25%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 17 + 5.8 + 3.4 = 41.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 19Visteon CorporationVC | 41.5/100Thin evidence · provisional56% evidence | ASLEEP | 14.1/35 Revenue — · PAT — · OPM change -5.4 pp 39% evidence | 11.4/25 ROCE 3.1% · OPM 4.3% 76% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 4.9/20 RS sector -8.1% · RS bench -10.8% · 1Y -7.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 11.4 + 11.1 + 4.9 = 41.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Dana IncorporatedDAN | 41.3/100Thin evidence · provisional51% evidence | ASLEEP | 18.1/35 Revenue 1.2% · PAT — · OPM change 2.7 pp 40% evidence | 7.8/25 ROCE 1.3% · OPM 3.2% 57% evidence | 11.5/20 P/E 3.1× · PEG — 15% evidence | 3.9/20 RS sector -5.9% · RS bench -8.9% · 1Y 57.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 7.8 + 11.5 + 3.9 = 41.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Aptiv PLCAPTV | 40.7/100Mixed-negative evidence61% evidence | ASLEEP | 15.5/35 Revenue 5.2% · PAT -75.7% · OPM change -1.9 pp 40% evidence | 9.8/25 ROCE 2% · OPM 7.4% 57% evidence | 13.9/20 P/E 41.1× · PEG 0.67 65% evidence | 1.5/20 RS sector -39% · RS bench -40.9% · 1Y -28.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 9.8 + 13.9 + 1.5 = 40.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22LKQ CorporationLKQ | 40.4/100Thin evidence · provisional56% evidence | BASING | 16.1/35 Revenue — · PAT — · OPM change -1.7 pp 39% evidence | 9.7/25 ROCE 1.8% · OPM 6.3% 76% evidence | 10.7/20 P/E 14.6× · PEG — 15% evidence | 3.9/20 RS sector -24% · RS bench -26.3% · 1Y -16.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 9.7 + 10.7 + 3.9 = 40.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23The Goodyear Tire & Rubber CompanyGT | 35.4/100Thin evidence · provisional56% evidence | TURNING | 10.7/35 Revenue -3.7% · PAT -1025.6% · OPM change -1.9 pp 53% evidence | 6.0/25 ROCE -0.7% · OPM -2.3% 57% evidence | 11.4/20 P/E 7.5× · PEG — 15% evidence | 7.3/20 RS sector -13.3% · RS bench -16% · 1Y -14%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 6 + 11.4 + 7.3 = 35.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24Mobileye Global Inc.MBLY | 34.7/100Thin evidence · provisional53% evidence | ASLEEP | 14.5/35 Revenue — · PAT — · OPM change -671.5 pp 39% evidence | 4.2/25 ROCE -0.3% · OPM -698.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.0/20 RS sector -24.4% · RS bench -26.6% · 1Y -36.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 4.2 + 10 + 6 = 34.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Versigent PLCVGNT | 53.4/100Thin evidence · provisional21% evidence | FADING | 18.0/35 Revenue — · PAT — · OPM change -0.8 pp 10% evidence | 14.4/25 ROCE 10.6% · OPM 6.2% 57% evidence | 11.0/20 P/E 13.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —5 of 6 weeks ahead 0% evidence |
| Exact sum: 18 + 14.4 + 11 + 10 = 53.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Aurora Innovation, Inc.AUR | 47.6/100Thin evidence · provisional44% evidence | ASLEEP | 14.0/35 Revenue — · PAT — · OPM change -14731.4 pp 26% evidence | 5.0/25 ROCE -12.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 18.6/20 RS sector 27.1% · RS bench 23.3% · 1Y 17.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14 + 5 + 10 + 18.6 = 47.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Adient plcADNT | 44.1/100Thin evidence · provisional45% evidence | BASING | 20.4/35 Revenue 3.8% · PAT — · OPM change 9.3 pp 40% evidence | 8.7/25 ROCE 2.5% · OPM 3.3% 57% evidence | 9.3/20 P/E 28.5× · PEG — 15% evidence | 5.7/20 RS sector -10.1% · RS bench -13% · 1Y -3.8%0 of 12 weeks ahead 70% evidence |
| Exact sum: 20.4 + 8.7 + 9.3 + 5.7 = 44.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Dauch CorporationDCH | 34.8/100Thin evidence · provisional50% evidence | BASING | 12.9/35 Revenue 14.8% · PAT -704.8% · OPM change -4.4 pp 53% evidence | 6.6/25 ROCE -0.5% · OPM -1.4% 57% evidence | 10.3/20 P/E 18.2× · PEG — 15% evidence | 5.0/20 RS sector -11.3% · RS bench -14.1% · 1Y 13.4%1 of 12 weeks ahead 70% evidence |
| Exact sum: 12.9 + 6.6 + 10.3 + 5 = 34.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29QuantumScape CorporationQS | 33.1/100Thin evidence · provisional47% evidence | ASLEEP | 17.4/35 Revenue — · PAT — · OPM change — 33% evidence | 5.2/25 ROCE -9.5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 0.5/20 RS sector -44.9% · RS bench -46.3% · 1Y -35%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 5.2 + 10 + 0.5 = 33.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is BorgWarner Inc.'s stock price today?
BorgWarner Inc. trades at $63.0, +68.0% over the past year. The company is valued at $13.0 B. The stock sits at 66% of its 52-week range of $41–$75, +14.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 46 weeks in. — as of 5 August 2026.
What were BorgWarner Inc.'s latest quarterly results?
BorgWarner Inc. reported revenue of $3.5 B and net profit of $0.3 B for the Mar 26 quarter. Revenue rose 0.3% and profit rose 52.9% year on year. Earnings per share were $1.16. The operating margin was 9.6%, 2.8 pp higher than a year earlier. — as of 5 August 2026.
What is BorgWarner Inc.'s revenue?
BorgWarner Inc. reported revenue of $3.5 B in the Mar 26 quarter, +0.3% year on year. For the full FY25 fiscal year, revenue was $14.3 B (+1.6%). Over the last 4 years revenue compounded at 5.0% a year. — as of 5 August 2026.
What is BorgWarner Inc.'s profit?
BorgWarner Inc. earned $0.3 B of net profit in the Mar 26 quarter, +52.9% year on year. Full-year FY25 profit was $0.3 B. The operating margin ran 9.6% in the latest quarter. — as of 5 August 2026.
What is BorgWarner Inc.'s market cap?
BorgWarner Inc.'s market capitalisation is $13.0 B at a stock price of $63.0. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is BorgWarner Inc.'s P/E ratio?
BorgWarner Inc. trades at a P/E of 37.3×, at the 80th percentile of its own 4-year range, against a long-run median of 13.5×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does BorgWarner Inc. pay a dividend?
Yes — BorgWarner Inc. declared $0.17 per share for Mar 26, and $0.62 per share across the last four reported quarters. The latest quarter is up 54.5% on the same quarter a year earlier. — as of 5 August 2026.
What is BorgWarner Inc.'s dividend per share?
BorgWarner Inc.'s most recently declared dividend is $0.17 per share for Mar 26, giving $0.62 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is BorgWarner Inc.'s dividend yield?
BorgWarner Inc.'s trailing dividend yield is 0.98%: $0.62 declared per share across the last four reported quarters, against a share price of $63.0. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is BorgWarner Inc. overvalued?
On its own history, BorgWarner Inc. looks expensive against its own history: its P/E of 37.3× sits at the 80th percentile of its 4-year range (long-run median 13.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is BorgWarner Inc. growing?
Yes — BorgWarner Inc. is growing: latest-quarter revenue +0.3% year on year, profit +52.9%, and the margin +2.8 pp at 9.6%. The 4-year compound rates are 5.0% (revenue) and −14.6% (profit). The earnings engine currently reads: improving — as of 5 August 2026.
How is BorgWarner Inc. performing?
BorgWarner Inc. is in a confirmed uptrend, 46 weeks in. Its latest quarter's revenue rose 0.3% and profit rose 52.9% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is BorgWarner Inc. in?
Turning around — profit growth swung from −66.7% at the trough to +20.0%, a 2-quarter improving streak, ROCE holding at 6.1%. The read comes from the last 12 quarters of growth (revenue growth +2.3% latest, profit growth +20.0% latest, eps growth +27.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is BorgWarner Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 46 of stage 2), trading +14.6% versus its 200-day average and at 66% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is BorgWarner Inc. beating the market?
Not lately — on a trailing-13-week view BorgWarner Inc. is currently behind the S&P 500 (1 week and counting; last ahead the week of 2026-07-31), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +106% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will BorgWarner Inc.'s stock price go up?
This page publishes no price forecast for BorgWarner Inc. What it measures instead: the stock price is $63.0, the price is in a confirmed uptrend 46 weeks in. Its P/E of 37.3× sits at the 80th percentile of its own 4-year range. — as of 5 August 2026.
Is the market betting against BorgWarner Inc.?
Somewhat — short interest is 4.5% of BorgWarner Inc.'s tradable float, about 3.5 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does BorgWarner Inc. have too much debt?
It is moderate — BorgWarner Inc.'s debt-to-equity is 0.72. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is BorgWarner Inc.'s capex?
BorgWarner Inc. spent $2.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.5 B. — as of 5 August 2026.
What is BorgWarner Inc.'s cash flow?
BorgWarner Inc. generated $1.6 B of operating cash flow in FY25 and $1.2 B of free cash flow after $0.5 B of capital spending. Reported profit that year was $0.3 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is BorgWarner Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 310% of BorgWarner Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $1.6 B against reported profit of $0.3 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is BorgWarner Inc.?
On the balance sheet, the Z-score reads 3.06 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is BorgWarner Inc. in its business cycle?
BorgWarner Inc.'s FY25 operating margin was 3.8%, against a 5-year band of 3.8%–8.2%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 9.6%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the BorgWarner Inc. story?
The sharpest disagreement: the price moved +68.0% in a year while annual EPS moved −14.7% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is BorgWarner Inc. a stock worth studying right now?
This is not investment advice. The machine read: BorgWarner Inc.'s price has outrun its earnings. +68.0% in a year against EPS −14.7% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.